Compare VTOL & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTOL | PRCT |
|---|---|---|
| Founded | 1948 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2011 | 2021 |
| Metric | VTOL | PRCT |
|---|---|---|
| Price | $46.57 | $25.09 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $58.00 | $35.44 |
| AVG Volume (30 Days) | 155.6K | ★ 1.1M |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | ★ 1.07% | N/A |
| EPS Growth | ★ 34.58 | 1.71 |
| EPS | ★ 4.32 | N/A |
| Revenue | ★ $1,490,512,000.00 | $308,054,000.00 |
| Revenue This Year | $11.64 | $31.34 |
| Revenue Next Year | $5.59 | $24.52 |
| P/E Ratio | $10.78 | ★ N/A |
| Revenue Growth | 5.30 | ★ 37.22 |
| 52 Week Low | $26.53 | $19.35 |
| 52 Week High | $50.28 | $64.89 |
| Indicator | VTOL | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 45.49 | 49.85 |
| Support Level | $42.83 | $22.81 |
| Resistance Level | $49.91 | $28.57 |
| Average True Range (ATR) | 1.32 | 1.18 |
| MACD | -0.32 | 0.21 |
| Stochastic Oscillator | 5.76 | 70.90 |
Bristow Group Inc is the provider of vertical flight solutions. The group provides aviation services to a broad base of offshore energy companies and government entities. Its business comprises three reportable segments: Offshore Energy Services, Government Services, and Other Services. Its customers in Australia, Brazil, Canada, Chile, the Dutch Caribbean, the Falkland Islands, India, Ireland, the Kingdom of Saudi Arabia, Mexico, the Netherlands, Nigeria, Norway, Spain, Suriname, Trinidad, the UK, and the U.S. offshore energy customers use services to transport personnel to, from and between offshore energy installations.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.